A detailed history of Northern Trust Corp transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 317,805 shares of YMAB stock, worth $4.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
317,805
Previous 321,715 1.22%
Holding current value
$4.12 Million
Previous $5.23 Million 26.61%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$11.6 - $17.25 $45,356 - $67,447
-3,910 Reduced 1.22%
317,805 $3.84 Million
Q1 2024

May 14, 2024

SELL
$6.57 - $18.69 $24,466 - $69,601
-3,724 Reduced 1.14%
321,715 $5.23 Million
Q4 2023

Feb 13, 2024

BUY
$4.88 - $7.42 $10,989 - $16,709
2,252 Added 0.7%
325,439 $2.22 Million
Q3 2023

Nov 13, 2023

SELL
$4.86 - $7.23 $25,928 - $38,572
-5,335 Reduced 1.62%
323,187 $1.76 Million
Q2 2023

Aug 11, 2023

BUY
$5.68 - $10.34 $148,776 - $270,835
26,193 Added 8.66%
328,522 $2.23 Million
Q1 2023

May 15, 2023

SELL
$2.83 - $5.11 $51,172 - $92,399
-18,082 Reduced 5.64%
302,329 $1.51 Million
Q4 2022

Feb 13, 2023

SELL
$3.0 - $15.17 $25,836 - $130,644
-8,612 Reduced 2.62%
320,411 $1.56 Million
Q3 2022

Nov 14, 2022

SELL
$13.96 - $19.67 $56,887 - $80,155
-4,075 Reduced 1.22%
329,023 $4.75 Million
Q2 2022

Aug 12, 2022

BUY
$8.22 - $15.13 $48,045 - $88,434
5,845 Added 1.79%
333,098 $5.04 Million
Q1 2022

May 13, 2022

SELL
$6.55 - $17.42 $109,607 - $291,506
-16,734 Reduced 4.86%
327,253 $3.89 Million
Q4 2021

Feb 08, 2022

SELL
$15.51 - $29.31 $47,258 - $89,307
-3,047 Reduced 0.88%
343,987 $5.58 Million
Q3 2021

Nov 15, 2021

BUY
$27.47 - $37.31 $17,251 - $23,430
628 Added 0.18%
347,034 $9.9 Million
Q2 2021

Aug 13, 2021

BUY
$25.45 - $37.64 $15,397 - $22,772
605 Added 0.17%
346,406 $11.7 Million
Q1 2021

May 12, 2021

SELL
$29.16 - $51.96 $212,809 - $379,204
-7,298 Reduced 2.07%
345,801 $10.5 Million
Q4 2020

Feb 11, 2021

SELL
$37.86 - $54.26 $798,732 - $1.14 Million
-21,097 Reduced 5.64%
353,099 $17.5 Million
Q3 2020

Nov 16, 2020

SELL
$35.13 - $43.62 $177,757 - $220,717
-5,060 Reduced 1.33%
374,196 $14.4 Million
Q2 2020

Aug 14, 2020

BUY
$23.66 - $49.53 $1.96 Million - $4.1 Million
82,770 Added 27.92%
379,256 $16.4 Million
Q1 2020

May 14, 2020

BUY
$14.39 - $35.8 $109,191 - $271,650
7,588 Added 2.63%
296,486 $7.74 Million
Q4 2019

Feb 14, 2020

BUY
$23.81 - $33.78 $989,829 - $1.4 Million
41,572 Added 16.81%
288,898 $9.03 Million
Q3 2019

Nov 13, 2019

BUY
$21.57 - $31.37 $2.88 Million - $4.18 Million
133,303 Added 116.91%
247,326 $6.45 Million
Q2 2019

Aug 13, 2019

BUY
$19.51 - $28.31 $634,679 - $920,952
32,531 Added 39.92%
114,023 $2.61 Million
Q1 2019

May 13, 2019

BUY
$18.21 - $26.21 $112,228 - $161,532
6,163 Added 8.18%
81,492 $2.14 Million
Q4 2018

Feb 12, 2019

BUY
$15.41 - $28.92 $1.16 Million - $2.18 Million
75,329 New
75,329 $1.53 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $566M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.